Cybin Inc. (HELP NASDAQ) stock market data APIs
$10.572
0.38(3.6%)
as of October 16, 2026
Try our APIs with
free plan!
Cybin Inc. Financial Data Overview
Price chart is built with
Anychart
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.
Prev. Close
10.572
Open
10.9567
High
10.9613
Low
10.3199
52 wk Range
3.76-15.15
Market Cap
771 M
Shares Outstanding
73 060 K
EPS
-0.91
Beta
0.539
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cybin Inc. data using free add-ons & libraries
Get Cybin Inc. Fundamental Data
Cybin Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -166 936 000
- Earnings Per Share: -4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-14
- EPS/Forecast: -0.8
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cybin Inc. News
New
Cybin (HELP) Stock May Be Trading At A Premium Despite Fresh Depression Trial Data
Cybin has delivered a 114.8% gain over the past year, which puts a spotlight on whether that kind of share price reset still lines up with what its balance sheet and book value suggest the stock is wo...
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board
Key Points Interested in Cybin Inc.? Here are five stocks we like better. Cybin, doing business as Helus Pharma, asked shareholders to approve changing the corporate name to Helus Pharma Inc. and set...
FDA names acting heads of drug and vaccine units to permanent roles
[FDA Headquarters] The Trump administration on Tuesday appointed the acting heads of the FDA units overseeing drugs, vaccines, and tobacco to permanent positions weeks after nominating White House ad...
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
Helus Pharma CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT. NEW YORK and TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HEL...
Get Cybin Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.